Form 4: Rocket Pharmaceuticals' General Counsel, Martin Wilson, Sells 4,100 Shares

Martin Wilson, General Counsel of Rocket Pharmaceuticals, sold 4,100 shares of common stock on February 29, 2024, at an average price of $29.331 per share.

Summary

• On February 29, 2024, Martin Wilson, the General Counsel of Rocket Pharmaceuticals, sold 4,100 shares of the company's common stock.
• The shares were sold at a weighted average price of $29.331.
• The sales occurred in multiple transactions with prices ranging from $29.33 to $29.37.
• Following the reported transaction, Wilson beneficially owns 18,680 shares of Rocket Pharmaceuticals' common stock directly.
• The transaction was reported on March 4, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a sale of shares by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock and future prospects. However, it's important to note that insider sales don't necessarily indicate a negative outlook, as they can be driven by various personal financial considerations.

Stakeholder Impact

• The sale of shares by a company insider could potentially influence investor sentiment, although the impact is likely to be minimal given the relatively small number of shares involved.

Key Dates